ReviewFuture medicinal chemistry2018
Strategies against methicillin-resistant Staphylococcus aureus persisters.
Review in Future medicinal chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti-Antimicrobial agents and chemotherapy · 2019Trial
- Ιdentification of SQ109 analogs with enhanced antimicrobial activity against methicillin-resistantAntimicrobial agents and chemotherapy · 2026Article
- Beta Carboline Alkaloid Harmine as Biofilm Inhibitor: In vitro, in Silico and in Vivo Studies Suppressing Growth and Virulence-Related Factors Against Resistant Staphylococcus Aureus.Applied biochemistry and biotechnology · 2026Article
- Antibacterial mechanism of hyper-branched poly-L-lysine against methicillin-resistantFrontiers in microbiology · 2025Article
- Bakuchiol killsFrontiers in pharmacology · 2025Article
- Comprehensive safety and toxicity analysis of 2,2'-Bipyridine derivatives in combating MRSA biofilm formation and persistence.Frontiers in cellular and infection microbiology · 2025Article
- Anti-Biofilm Effect of Hybrid Nanocomposite Functionalized with Erythrosine B onMolecules (Basel, Switzerland) · 2024Article
- Treatment of MRSA Infection: Where are We?Current medicinal chemistry · 2024Review
- Pheromone cCF10 inhibits the antibiotic persistence ofFrontiers in microbiology · 2024Article
- Genomic characterization and outbreak investigations of methicillin-resistantFrontiers in microbiology · 2024Article
- Antimicrobial activity of nature-inspired molecules against multidrug-resistant bacteria.Frontiers in microbiology · 2023Article
- Synergistic effect of antibiotic combinations onBiofilm · 2022Article
- Silver Carboxylate as an Antibiotic-Independent Antimicrobial: A Review of Current Formulations,Medical research archives · 2022Article
- Review
- Proton Motive Force Inhibitors Are Detrimental to Methicillin-Resistant Staphylococcus aureus Strains.Microbiology spectrum · 2022Article
- Leucyl-tRNA Synthetase Inhibitor, D-Norvaline, in Combination with Oxacillin, Is Effective against Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Antibacterial Activity of Small Molecules Which Eradicate Methicillin-ResistantFrontiers in microbiology · 2022Article
- Technologies for High-Throughput Identification of Antibiotic Mechanism of Action.Antibiotics (Basel, Switzerland) · 2021Review
- Physico-Chemical Characterization and Antimicrobial Properties of Hybrid Film Based on Saponite and Phloxine B.Molecules (Basel, Switzerland) · 2021Article
- Enzyme-Functionalized Mesoporous Silica Nanoparticles to TargetInternational journal of nanomedicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Chronic Staphylococcus aureus infections are complicated by frequent relapses not only from the development of drug resistance to conventional antibiotics, but also through the formation of persister bacterial cells. Bacterial persisters are in a transient, metabolically inactive state, making conventional antibiotics that target essential cellular growth processes ineffective, resulting in high clinical failure rates of antibiotic chemotherapy. The development of new antibiotics against persistent S. aureus is an urgent issue. Over the last decade, new strategies to identify S. aureus persister-active compounds have been proposed. This review summarizes the proposed targets, antipersister compounds and innovative methods that may augment conventional antibiotics against S. aureus persisters. The reviewed antipersister strategies can be summarized as two broad categories; directly targeting growth-independent targets and potentiating existing, ineffective antibiotics by aiding uptake or accessibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.